# DEC 2 3 2005

# 510K SUMMARY

# This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92

The assigned 510(k) number is: K052826

# COMPANYICONTACT PERSON

Seradyn, Inc   
7998 Georgetown Road, Suite 1000   
Indianapolis, IN 46268

Establishment registration No: 1836010

Jack Rogers Manager of Regulatory Affairs Telephone: (317) 610-3823 Fax: (317) 610-0018

# DATE PREPARED

October 4, 2005

# DEVICE NAME

Trade Name: $\mathsf { Q M S } ^ { \otimes }$ Quinidine Common Name: Homogeneous Particle-Enhanced Turbidimetric Immunoassay Device Classification: 21 CFR 862.3320; Enzyme Immunoassay, Quinidine; Class II

# INTENDED USE

The QMS® Quinidine assay is intended for the quantitative determination of quinidine in human serum or plasma on automated clinical chemistry analyzers.

The results obtained are used in the diagnosis and treatment f quinidine overdose and in monitoring levels oqunidine to help ensure appropriate therapy.

# LEGALLY MARKETED DEVICE TO WHICH EQUIVALENCY IS CLAIMED

Abbott TDx/TDxFLx Quinidine

# DESCRIPTION OF DEVICE

The $\mathsf { Q M S } ^ { \otimes }$ Quinidine assay system is a homogeneous assay utilizing particle agglutination technology and is based on the competitive binding principle.

In partcgglutination assays,thdegreglutinatin isnverely roortional tohequantiy drug in the reaction well. Hence, if no drug is present in the sample, the antibodies in the $\mathsf { Q M S } ^ { \otimes }$ Quinidine Antboy Reagent (R) wil ind ny he boud drgn he partice which wilcause  toaglutia and will result inhigher absobanncreas amount  cpetig dr s present i the sample,ill result in decreased binding of bound drug by the antibody, resulting in a relative decrease in particle agglutination. This in turn results in lower absorbance.

The precise relationship between particle agglutination and concentration of the unlabeled drug in the sample is established by measuring the absorbance values of calibrators with known concentration of the drug. The absorbance of unknown samples can be interpolated from the absorbance values of the calibration curve and the concentration of the drug present in the sample can be calculated.

The assay consists of reagents R1: anti-quinidine monoclonal antibody and R2: quinidine-coated microparticles. A six-level set of $\ Q M S ^ { \otimes }$ Quinidine Calibrators (A through F) is used to calibrate the assay.

COMPARISON OF TECHNOLOGICAL CHARACTERISTICS   

<table><tr><td rowspan=1 colspan=1>DeviceSeradyn QMS® Quinidine</td><td rowspan=1 colspan=1>PredicateAbbott TDx/TDxFLx Quinidine</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The QMS Quinidine assay isintended   for   the   quantitativedetermination of quinidine in humanserum or plasma on automatedclinical chemistry analyzers.</td><td rowspan=1 colspan=1>The TDx/TDxFIx Quinidine assay is areagent system for the quantitativemeasurement of quinidine in serum orplasma.</td></tr><tr><td rowspan=1 colspan=1>indicationsfor Use</td><td rowspan=1 colspan=1>The measurements obtained are usedin the diagnosis and treatment ofquinidine overdose and in monitoringlevels of quinidine to ensureappropriate therapy.</td><td rowspan=1 colspan=1>The measurements obtained are usedin monitoring levels of quinidine toensure appropriate therapy.</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogeneous particle-enhancedturbidimetric immunoassay (particleagglutination)</td><td rowspan=1 colspan=1>Fluorescence Polarizationimmunoassay (FPIA) technology.</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-Quinidine Antibody Reagent(R1) in buffers containing proteinstabilizers with sodium azideQuinidine-coated MicroparticleReagent (R2) in buffer containingsurfactant as stabilizers withsodium azide</td><td rowspan=1 colspan=1>Three (3) reagent system:Pretreatment Solution (P)Surfactant in buffer containing N-N-dimethylformamide and proteinstabilizer and sodium azide.S Quinidine Antiserum (Goat) inbuffer with protein stabilizer andSodium azide.T Quinidine Fluorescein Tracer inbuffer with protein stabilizersurfactant N-N-dimethylIformamideand Sodium azide</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>QMS QuinidineCalibrators - six levels</td><td rowspan=1 colspan=1>X Systems QuinidineCalibrators - six levels</td></tr></table>

# SUMMARY OF CLINICAL TESTING

# Accuracy

Accuracy by Recovery was determined by spiking USP traceable quinidine into human serum negative for the drug to achieve concentrations across the assay range.The samples were analyzed in duplicate with the QMS Quinidine assay.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μg/mL)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% RecoveryAcceptanceCriteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.06</td><td rowspan=1 colspan=1>1.81</td><td rowspan=1 colspan=1>1.94</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>6.50</td><td rowspan=1 colspan=1>97.00</td></tr><tr><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.94</td><td rowspan=1 colspan=1>3.95</td><td rowspan=1 colspan=1>3.95</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>98.75</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>7.81</td><td rowspan=1 colspan=1>7.76</td><td rowspan=1 colspan=1>7.79</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>97.38</td></tr><tr><td rowspan=1 colspan=6>Mean Percent Recovery</td><td rowspan=1 colspan=1>97.71</td></tr></table>

# Linearity

Linearity by Dilution was determined by a study based on the NCCLS guideline EP6: Evaluation of the Linearity of Quantitative Measurement.

Alinear regression analysis plot of USP Quinidine against recovered quinidine resulted in a line with a correlation coefficient $( { \mathsf { R } } ^ { 2 } )$ of 0.9995, demonstrating that the assay is linear.

<table><tr><td rowspan=1 colspan=1>THEORETICALCONC.(μg/mL)</td><td rowspan=1 colspan=1>Rep 1</td><td rowspan=1 colspan=1>Rep 2</td><td rowspan=1 colspan=1>MeanRecoveredConc.</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>15.90</td><td rowspan=1 colspan=1>88.00</td></tr><tr><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.71</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>0.72</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>96.00</td></tr><tr><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>94.67</td></tr><tr><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.98</td><td rowspan=1 colspan=1>2.98</td><td rowspan=1 colspan=1>2.98</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>99.33</td></tr><tr><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>6.22</td><td rowspan=1 colspan=1>6.18</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>103.33</td></tr><tr><td rowspan=1 colspan=6>Mean Percent Recovery</td><td rowspan=1 colspan=1>96.27</td></tr></table>

# Sensitivity

The Analytical Sensitivity or Least Detectable Dose (LDD) of the assay is defined as the concentration at which the lowest concentration is distinguishable from zero with $9 5 \%$ confidence.

The average LDD is $0 . 0 9 \ : \mu \mathfrak { g } / \mathfrak { m } \ : L$ , supporting a claim of $0 . 2 \mu \ g / m L$ .

# Assay Range

Based on the Accuracy, Linearity, and Sensitivity (LDD) data, the package insert claim for the reporable range for the assay will be 0.2 to $8 . 0 \mu \ g / m L$ .

# Method Comparison

A study was conducted according to NCCLS Guideline EP9: Method Comparison and Bias Estimation Using Patient Samples to compare accuracy of recovery of quinidine in serum assayed by the $\mathsf { Q M S } ^ { \otimes }$ Quinidine assay to the Abbott TDx/TDxFLx® Quinidine assay.

Mean values for the TDx reference method were plotted against those for the QMS on Hitachi 717. The results using Passing - Bablok parameters are:

$N = 5 0$   
Slope $= 1 . 0 6 2$   
y-intercept $\pmb { = } - 0 . 2 1 3$   
$R ^ { 2 } = 0 . 9 7 8$

Results show excellent correlation between the two assays.

# Precision

A precision study was performed using the National Commitee for Clinical Laboratory Standards (NCCLS) guideline EP5: Evaluation of Precision Performance of Clinical Chemistry Devices.   

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>BETWEEN DAY</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(μg/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.83</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.53</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>9.09</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.17</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>2.45</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>6.37</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.62</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>5.83</td></tr></table>

Acceptance Criteria: $< 1 0 \%$ total CV

# Specificity

Metabolites of quinidine include: 3-Hydroxyquinidine; Quinidine-N-oxide; O-Desmethylquinidine; 2-Oxoquinidinone; and 10,11-Dihydroquinidinediol. The most important metabolite is 3-Hydroxyquinidine, serum levels of which can approach those of quinidine in patints receiving conventional doses of thedrug. It is also reported to have an antiarrhythmic potency similar to that of quinidine.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>ControlMean</td><td rowspan=1 colspan=1>Conc. Of Cross-reactant spikedμg/mL</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>Da-Dt</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>3-Hydroxyquinidine</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.71</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.78</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>2.01</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>1.27</td></tr><tr><td rowspan=1 colspan=1>Quinidine-N-oxide</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.99</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>3.28</td><td rowspan=1 colspan=1>65.60</td></tr><tr><td rowspan=1 colspan=1>O-Desmethylquinidine</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.72</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6.55</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>0.84</td><td rowspan=1 colspan=1>16.80</td></tr><tr><td rowspan=1 colspan=1>2-Oxoquinidinone</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.71</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>6.09</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.47</td><td rowspan=1 colspan=1>0.38</td><td rowspan=1 colspan=1>7.60</td></tr><tr><td rowspan=1 colspan=1>10,11-Dihydroquinidinediol</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5.37</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5.99</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>2.81</td><td rowspan=1 colspan=1>0.63</td><td rowspan=1 colspan=1>12.53</td></tr></table>

# Interferences

Interference studies were conducted using NCCLS Guideline EP7: Interference Testing in Clinical Chmistry.

# 1)Endogenous Substances

<table><tr><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>InterferentConcentration</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Target(No Interferent)μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/mL</td><td rowspan=1 colspan=1>% RecoveryAcceptanceCriteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>15 mg/dL</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.82</td><td rowspan=1 colspan=1>5.98</td><td rowspan=1 colspan=1>103.0</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>10 g/L</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.82</td><td rowspan=1 colspan=1>5.84</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Triglyceride</td><td rowspan=1 colspan=1>1127 mg/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6.05</td><td rowspan=1 colspan=1>5.58</td><td rowspan=1 colspan=1>92.18</td></tr><tr><td rowspan=1 colspan=1>Total Protein</td><td rowspan=1 colspan=1>12 g/dL</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>6.32</td><td rowspan=1 colspan=1>6.30</td><td rowspan=1 colspan=1>99.68</td></tr></table>

# HAMA

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Rep 1μg/mL</td><td rowspan=1 colspan=1>Rep 2μg/mL</td><td rowspan=1 colspan=1>MeanRecoveryμg/ml</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>% RecoveryAcceptance Criteria:100±10%</td></tr><tr><td rowspan=1 colspan=1>Control</td><td rowspan=1 colspan=1>6.59</td><td rowspan=1 colspan=1>6.24</td><td rowspan=1 colspan=1>6.42</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>2.73</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HAMA Type-1</td><td rowspan=1 colspan=1>5.79</td><td rowspan=1 colspan=1>5.91</td><td rowspan=1 colspan=1>5.85</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>1.37</td><td rowspan=1 colspan=1>91.12</td></tr><tr><td rowspan=1 colspan=1>HAMA Type-2</td><td rowspan=1 colspan=1>5.80</td><td rowspan=1 colspan=1>5.84</td><td rowspan=1 colspan=1>5.82</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.34</td><td rowspan=1 colspan=1>90.65</td></tr></table>

# Common Co-Administered Drugs

<table><tr><td rowspan=1 colspan=1>Cross-reactant Drug</td><td rowspan=1 colspan=1>Conc. Testedµg/mL</td><td rowspan=1 colspan=1>Percent Cross-Reactivity/Conc(μg/mL)</td></tr><tr><td rowspan=1 colspan=1>Acetominophen</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>NO</td></tr><tr><td rowspan=1 colspan=1>Acetyl cysteine</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Acetylsalycilic acid</td><td rowspan=1 colspan=1>3000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>-0.51</td></tr><tr><td rowspan=1 colspan=1>Cefoxitin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Cyclosporine</td><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Digitoxin</td><td rowspan=1 colspan=1>0.25</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Digoxin</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.02</td></tr><tr><td rowspan=1 colspan=1>Disopyramide</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0.76</td></tr><tr><td rowspan=1 colspan=1>Ephedrin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Hydrochlorothiazide</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>7000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Isoproterenol</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Levodpa</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Lidocaine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>N-Acetylprocainamide</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Phenytoin (DPH)</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Procainamide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Propranolol</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4.33</td></tr><tr><td rowspan=1 colspan=1>Quinine</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14.80</td></tr><tr><td rowspan=1 colspan=1>Reserpine</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>2000</td><td rowspan=1 colspan=1>ND</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>ND</td></tr></table>

\*ND $\equiv$ not detected

# Anticoagulants

Studies were conducted to determine the performance characteristics of the assay for both serum and plasma samples containing quinidine.

The results indicate that there is no significant diference between the recovery of quinidine in serum o plasma. The collection tubes evaluated show no adverse effects on the recovery of quinidine, within the experimental error for the spiking study.

A claim for assay application to both serum and plasma samples is thus supported.

# On-Board Stability

Calibration Curve stability Calibration curve stability of a period of 28 days is supported by the data.

# Reagent On-Board Stability

A 25 day on-board reagent stability claim is supported by the data.

# CONCLUSION

As summarized above, the QMS® Quinidine assay is substantially equivalent to the Abbott TDx®TDxFLx® Quinidine assay.Substantial equivalence has been demonstrated through performance testing to veriy that the device functions as intended and that design specifications have been satisfied.

# DEC 2 3 2005

Mr. Jack Roger   
Manager of Regulatory Affairs Seradyn, Inc.   
7998 Georgetown Road   
Suite 100   
Indianapolis, IN 46268

Re: k052826 Trade/Device Name: QMS $^ \mathrm { \textregistered }$ Quinidine Regulation Number: 21 CFR 862.3320 Regulation Name: Digoxin test system Regulatory Class: Class II Product Code: LBZ Dated: October 4, 2005 Received: October 5, 2005

Dear Mr. Rogers:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations afecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/70fb6ccb6d5929418c5f37e58c71acb5233310a4c2878600c91c574868cb48d3.jpg)

Alberto Gutierrez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K052826

Device Name: EPY $\mathsf { Q M S } ^ { \circledast }$ Quinidine

# Indications for Use:

The QMS® Quinidine assay is intended for the quantitative determination of auinidine in human serum or plasma on automated clinical chemistry analyzers.

The results obtained are used in the diagnosis and treatment of quinidine overdose and in monitoring levels of quinidine to help ensure appropriate therapy.

# (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

# Office of In Vitro Diagnostic Device Evaluation and Safety